Scientometric analysis of chemotherapy of canine leishmaniasis (2000-2020)
- PMID: 33422141
- PMCID: PMC7796616
- DOI: 10.1186/s13071-020-04544-x
Scientometric analysis of chemotherapy of canine leishmaniasis (2000-2020)
Abstract
Background: Zoonotic visceral leishmaniasis by Leishmania infantum is a first-order pathology in canine veterinary clinics in endemic areas. Moreover, canine infections are considered the main reservoir for human disease; despite their importance in the control of the disease within a One Health approach, no scientometric study has been published. Aims of the study included analyzing the impact of canine leishmaniasis (CanL) on the scientific literature, drugs or combinations used, trends in the period from 2000 to 2020 and efficacy criteria employed.
Methods: A Web of Science (WOS)-based analysis of publications on CanL and chemotherapy of the disease in the period 2000-2020 was carried out using a stepwise methodology. Data were analyzed by year, geographical origin, chemical groups, drugs and combinations, and efficacy criteria.
Results: Reports on CanL (n = 3324) represented < 16% of all publications on leishmaniasis (n = 20,968), and of these around 18% (n = 596) were related to chemotherapy. Publication records on CanL followed the distribution of the infection by L. infantum in endemic areas although Mediterranean countries were overrepresented in the reports on chemotherapy of CanL. Publications on the main antileishmanial drugs used in clinical practice showed a sustained tendency in the period analyzed. Pentavalent antimonials (SbV), alone or in combination with allopurinol, represented > 50% of all publications on chemotherapy of CanL despite the availability of more recently marketed drugs.
Conclusions: Chemotherapy of CanL still relies on SbV and combinations and to a lesser extent on miltefosine (MIL). Reports on chemotherapy are scarce and mostly publicly funded, and the variability of experimental conditions hampers the direct comparison of the efficacy of drugs, combinations and schedules. The vast majority of reports on efficacy do not include any information on supportive therapy; this reduces the actual value of the studies if intended for the practical management of the disease. Complete reports on the chemotherapy (etiological + symptomatic) would add value to the trials performed.
Keywords: Allopurinol; Amphotericin; Antimonials; Canine leishmaniasis; Chemotherapy; Leishmania infantum; Leishmania spp.; Miltefosine; SbV.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures



Similar articles
-
[Canine leishmaniasis: evolution of the chemotherapeutic protocols].Parassitologia. 2004 Jun;46(1-2):231-4. Parassitologia. 2004. PMID: 15305724 Review. Italian.
-
Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.Parasit Vectors. 2021 Dec 9;14(1):599. doi: 10.1186/s13071-021-05100-x. Parasit Vectors. 2021. PMID: 34886876 Free PMC article.
-
In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.Exp Parasitol. 2013 Sep;135(1):36-41. doi: 10.1016/j.exppara.2013.05.015. Epub 2013 Jun 6. Exp Parasitol. 2013. PMID: 23747751
-
Current status on prevention and treatment of canine leishmaniasis.Vet Parasitol. 2016 Aug 30;227:98-114. doi: 10.1016/j.vetpar.2016.07.011. Epub 2016 Jul 12. Vet Parasitol. 2016. PMID: 27523945 Review.
-
Diagnosis and clinical management of canine leishmaniosis by general veterinary practitioners: a questionnaire-based survey in Portugal.Parasit Vectors. 2021 Jun 7;14(1):306. doi: 10.1186/s13071-021-04799-y. Parasit Vectors. 2021. PMID: 34099039 Free PMC article.
Cited by
-
Nutritional Modulation of the Immune Response Mediated by Nucleotides in Canine Leishmaniosis.Microorganisms. 2021 Dec 16;9(12):2601. doi: 10.3390/microorganisms9122601. Microorganisms. 2021. PMID: 34946204 Free PMC article. Review.
-
Bibliometric Analysis of Veterinary Communication Education Research over the Last Two Decades: Rare Yet Essential.Vet Sci. 2022 May 27;9(6):256. doi: 10.3390/vetsci9060256. Vet Sci. 2022. PMID: 35737308 Free PMC article.
-
Antileishmanial Drug Discovery and Development: Time to Reset the Model?Microorganisms. 2021 Dec 2;9(12):2500. doi: 10.3390/microorganisms9122500. Microorganisms. 2021. PMID: 34946102 Free PMC article. Review.
-
In Vitro Evaluation of Aerosol Therapy with Pentamidine-Loaded Liposomes Coated with Chondroitin Sulfate or Heparin for the Treatment of Leishmaniasis.Pharmaceutics. 2023 Apr 6;15(4):1163. doi: 10.3390/pharmaceutics15041163. Pharmaceutics. 2023. PMID: 37111648 Free PMC article.
-
Characterisation and evaluation of predisposing factors for the development of xanthinuria in dogs with leishmaniosis under allopurinol therapy.Parasit Vectors. 2025 Mar 10;18(1):98. doi: 10.1186/s13071-025-06731-0. Parasit Vectors. 2025. PMID: 40065388 Free PMC article.
References
-
- WHO. World Health Organization: Leishmaniasis; 2020. http://www.who.int/gho/neglected_diseases/leishmaniasis/en/. Accessed 8 Mar 2020.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous